Alexander Kirichenko | Health Professions | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Alexander Kirichenko | Health Professions | Best Researcher Award

Professor Drexel University College of Medicine Drexellat at Allegheny General Hospital, United States

Dr. Alexander V. Kirichenko, MD, PhD, is a distinguished radiation oncologist and researcher with extensive expertise in stereotactic body radiotherapy (SBRT) and radiation biology. He currently serves as an Attending Radiation Oncologist at Allegheny General Hospital and System Director for Stereotactic Body Radiotherapy & Gastrointestinal Cancers Program at Allegheny Health Network Cancer Institute. With a career spanning over four decades, Dr. Kirichenko has made significant contributions to oncology research, particularly in hepatocellular carcinoma and functional treatment planning. His humanitarian efforts include leading international collaborations to advance radiation oncology care in Ukraine. A dedicated educator and innovator, Dr. Kirichenko has contributed to multiple clinical trials, patents, and book chapters, shaping the future of radiation oncology.

Professional Profile

Education

Dr. Kirichenko earned his MD from Kyiv Medical University, Ukraine, in 1981, followed by a residency in Radiation Oncology and Nuclear Medicine. He later obtained a PhD in Radiation Biology and a D.Sc. in Radiation Medicine. In pursuit of advanced training, he completed a postdoctoral fellowship at MD Anderson Cancer Center and obtained U.S. medical licensure from the University of Virginia. His residency training in General Surgery and Radiation Oncology at the University of Virginia further solidified his expertise. These rigorous academic and clinical experiences have enabled him to excel in both patient care and research.

Professional Experience

With a career dedicated to radiation oncology, Dr. Kirichenko has held various prestigious academic and clinical positions. He served as an Associate Professor at the Ukrainian National Cancer Institute and the University of Virginia before joining Allegheny General Hospital in 2006. As a leading expert, he has been involved in the development of advanced radiation therapies, including SBRT for liver malignancies. His work also extends to international collaborations, where he has played a pivotal role in enhancing global cancer care standards. His leadership within multiple healthcare institutions has made a lasting impact on cancer treatment methodologies.

Research Interests

Dr. Kirichenko’s research primarily focuses on radiation-induced toxicity, functional treatment planning, and advanced imaging techniques in radiation therapy. His studies on SBRT for hepatocellular carcinoma have contributed to improving survival outcomes while minimizing toxicity. He has also explored the use of superparamagnetic iron oxide nanoparticles (SPION) for enhancing MRI-guided radiotherapy. Through his involvement in numerous clinical trials and NIH-funded studies, he has pioneered innovative approaches in liver and rectal cancer treatment. His research continues to influence clinical practices, bridging the gap between experimental oncology and patient-centered care.

Awards and Honors

Throughout his career, Dr. Kirichenko has received numerous accolades for his contributions to radiation oncology. He has been recognized as one of the Best Doctors in America (2013–2023) and has received the Health Care Heroes Award from Pittsburgh Business Times. His leadership in national and international oncology projects has earned him appointments to expert panels, including the National Center for Biosecurity and Biodefense Preparedness. His extensive list of invited lectures, patents, and book chapters further reflects his commitment to advancing cancer research and treatment.

Conclusion

Dr. Alexander V. Kirichenko is a highly qualified and impactful researcher in radiation oncology with strong contributions to clinical innovation, translational research, and international collaboration. His extensive body of work, patents, leadership roles, and humanitarian contributions make him a strong candidate for the Best Researcher Award. If supplemented with further high-impact publications, mentorship initiatives, and policy engagements, his profile would be nearly unbeatable.

Publications Top Notes

  • Title: Chronomodulated chemotherapy and irradiation: An idea whose time has come?

  • Authors:

    • Tyvin A. Rich

    • Charles H. Shelton III

    • Alexander V. Kirichenko

    • Martin Straume

  • Journal: Chronobiology International

  • Year of Publication: 2002

  • Citations: 18 (as per available sources)

 

Carolin C. Hack | Medicine and Dentistry | Best Scholar Award

Posted on by ScienceFather

Dr. Carolin C. Hack | Medicine and Dentistry | Best Scholar Award

Deputy clinical director at Erlangen University Hospital Women’s Clinic, Germany

Priv.-Doz. Dr. med. Carolin Christine Hack is an accomplished medical professional and the Deputy Director of the Women’s Clinic at the University Hospital Erlangen. With a specialization in gynecological oncology and integrative medicine, Dr. Hack combines her clinical expertise with a passion for patient-centered care. Her innovative approach to medicine, along with her extensive training and research, positions her as a leading figure in her field.

Profile

Scopus

Education πŸŽ“

Dr. Hack completed her medical degree at Friedrich-Alexander University Erlangen-Nuremberg, where she also pursued her habilitation in β€œIntegrative Medicine in the Treatment of Gynecological Oncology Patients.” Her academic journey included a comprehensive curriculum that laid the groundwork for her clinical and research interests, ultimately leading to a robust foundation in both conventional and integrative medicine.

Experience πŸ’Ό

With over a decade of experience at the University Hospital Erlangen, Dr. Hack has advanced through various roles, from assistant physician to Deputy Director of the Women’s Clinic. She has managed quality assurance initiatives and specialized in integrative medicine, focusing on the intersection of traditional and complementary therapies in patient care. Her leadership in the clinic has fostered a collaborative environment that emphasizes innovative treatment methodologies.

Research Interests πŸ”

Dr. Hack’s research primarily focuses on integrative medicine and complementary therapy methods, with a specific emphasis on mammographic density as a risk factor for breast cancer. Her work seeks to enhance patient outcomes through evidence-based practices that incorporate holistic approaches to treatment.

Awards πŸ†

Dr. Hack’s contributions to gynecological oncology have been recognized with multiple awards, including:

  • 2015: Klaus-Dieter-Schulz-Versorgungsforschungspreis
  • 2016: First Science Award from the German Society for Senology
  • 2018: Award from the Foundation for Women and Child Health
  • 2022: Research Award for Complementary Medicine from NATUM e.V.

Publications πŸ“š

Dr. Hack has an extensive publication record, including:

  • The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
    • Authors: Ziegler, P., Hartkopf, A.D., Wallwiener, M., Schneeweiss, A., Goossens, C.
    • Journal: BMC Cancer
    • Year: 2024
    • Volume: 24(1), Article 1284
  • Tumor-Associated Neutrophils Are a Negative Prognostic Factor in Early Luminal Breast Cancers Lacking Immunosuppressive Macrophage Recruitment
    • Authors: Schmidt, E., Distel, L., Erber, R., Fietkau, R., Schnellhardt, S.
    • Journal: Cancers
    • Year: 2024
    • Volume: 16(18), Article 3160
  • Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole
    • Authors: Fasching, P.A., Hack, C.C., Nabieva, N., Fehm, T.N., HΓ€berle, L.
    • Journal: European Journal of Cancer
    • Year: 2024
    • Volume: 209, Article 114239
  • Correlation of RANK and RANKL with mammographic density in primary breast cancer patients
    • Authors: Wunderle, M., Heindl, F., Behrens, A.S., Fasching, P.A., Emons, J.
    • Journal: Archives of Gynecology and Obstetrics
    • Year: 2024
    • Volume: 310(2), pp. 1223–1233
  • CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – An Overview of Current Programs
    • Authors: Schneeweiss, A., Brucker, S.Y., Huebner, H., Fehm, T.N., Fasching, P.A.
    • Journal: Geburtshilfe und Frauenheilkunde
    • Year: 2024
    • Volume: 84(5), pp. 443–458
  • Initial experience with a next-generation low-field MRI scanner: Potential for breast imaging?
    • Authors: Dietzel, M., Laun, F.B., Heiß, R., Uder, M., Ohlmeyer, S.
    • Journal: European Journal of Radiology
    • Year: 2024
    • Volume: 173, Article 111352
  • Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer
    • Authors: Heger, L., Heidkamp, G.F., Amon, L., Beckmann, M.W., Dudziak, D.
    • Journal: OncoImmunology
    • Year: 2024
    • Volume: 13(1), Article 2296713
  • Predicting mammographic density with linear ultrasound transducers
    • Authors: Behrens, A., Fasching, P.A., Schwenke, E., Beckmann, M.W., Emons, J.
    • Journal: European Journal of Medical Research
    • Year: 2023
    • Volume: 28(1), Article 384
  • Evaluation of automated techniques for extraction of circulating cell-free DNA for implementation in standardized high-throughput workflows
    • Authors: Lehle, S., Emons, J., Hack, C.C., Ruebner, M., Huebner, H.
    • Journal: Scientific Reports
    • Year: 2023
    • Volume: 13(1), Article 373
  • Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
    • Authors: Hack, C.C., Maass, N., Aktas, B., Hein, A., Fasching, P.A.
    • Journal: Geburtshilfe und Frauenheilkunde
    • Year: 2023
    • Volume: 84(2), pp. 185–195

Conclusion ✨

Priv.-Doz. Dr. med. Carolin Christine Hack is an exemplary candidate for the Best Researcher Award. Her innovative contributions to integrative medicine and gynecological oncology, coupled with her extensive publication record and commitment to patient care, position her as a leader in her field. By addressing areas for improvement, such as interdisciplinary collaboration and public engagement, Dr. Hack can further enhance her impact in research and continue to advance the frontiers of medical knowledge.

Rima Isaifan | human health | Women Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Rima Isaifan | human health | Women Researcher Award

Associate Professor, Cambridge C University, Qatar

🌿 Dr. Rima Isaifan is an Associate Professor of Environmental Sciences at Cambridge Corporate University, Lucerne, Switzerland. With a Ph.D. in Chemical and Biological Engineering from the University of Ottawa, she has made significant contributions to the fields of sustainable development and environmental protection. Her extensive research focuses on climate change, greenhouse gas emissions, and sustainable urban development, particularly in the Middle Eastern context. 🌍

Publication Profile

Scopus

Education

πŸŽ“ Dr. Isaifan earned her Ph.D. in Chemical Engineering (Chemical and Biological Engineering) from the University of Ottawa in 2014. Her academic background blends environmental and chemical sciences, making her an expert in sustainable environmental solutions.

Experience

πŸ’Ό Currently an Associate Professor at Cambridge Corporate University, Switzerland, Dr. Isaifan has a wealth of teaching and research experience in environmental sciences. She has also collaborated with multiple research institutions, contributing her knowledge to various climate and sustainability initiatives in the Middle East.

Research Focus

πŸ”¬ Dr. Isaifan’s research revolves around environmental sustainability, climate change, and the social cost of greenhouse gas emissions. She has also explored urban development strategies, especially in the Middle East, focusing on sustainable transportation and urban renewal projects. Her work aims to create practical solutions to mitigate climate change. 🌱

Awards and Honors

πŸ… Dr. Isaifan’s outstanding contributions to environmental research and sustainability have earned her recognition in academic and professional communities. She continues to push boundaries in environmental policy and science, especially regarding climate change action in Arab countries. 🌍

Publication Highlights

πŸ“š Dr. Isaifan has published extensively in top-tier journals. Some of her notable works include:

Transit-Oriented Development in Middle Eastern Cities: The Urban Renewal Framework for the Souq Waqif in Doha, Qatar (2024) in Urban Science, DOI: 10.3390/urbansci8040182

Correction: Al-Jabir, M.; Isaifan, R.J. Long-Term Projection of Transport-Related Social Cost of Greenhouse Gas Emissions in Qatar (2024) in Sustainability, DOI: 10.3390/su16198422

Strategic plans to support action against climate change in the Arab countries in the Middle East Region (2024) in Journal of Sustainable Development Law and Policy, DOI: 10.4314/jsdlp.v15i1.11

Long-Term Projection of Transport-Related Social Cost of Greenhouse Gas Emissions in Qatar (2024) in Sustainability, DOI: 10.3390/su16020536

 

Shahab Reaeian | Prevention | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Shahab Reaeian | Prevention | Best Researcher Award

Academic member, Kermanshah University of Medical Sciences, Iran

Dr. Shahab Rezaeian is an esteemed epidemiologist from Iran, specializing in public health and epidemiology. With a PhD from Shiraz University of Medical Sciences, he has dedicated his career to understanding the dynamics of diseases and their impact on communities. He is currently a faculty member at Kermanshah University of Medical Sciences, contributing to the field through both research and education. πŸ©ΊπŸ“š

Publication Profile

Google scholar

Education

Dr. Rezaeian earned his B.S. in Public Health from Iran University of Medical Sciences in 2007, followed by an MSc in Epidemiology from Hamadan University of Medical Sciences in 2012. He completed his PhD in Epidemiology at Shiraz University of Medical Sciences in 2016, focusing his research on the survival trends and blood demand of beta-thalassemia patients. πŸŽ“

Experience

Dr. Rezaeian has extensive experience in epidemiological research, particularly in assessing the risk factors for various health conditions, including congenital hypothyroidism and HIV. His professional journey reflects a commitment to advancing public health through rigorous data analysis and interpretation. πŸ’Ό

Research Focus

His primary research interests include epidemiological modeling, public health interventions, and the study of congenital conditions. Dr. Rezaeian aims to contribute to effective health policies and practices by analyzing health data and identifying key determinants of health outcomes. πŸ”¬πŸ“ˆ

Awards and Honours

Dr. Rezaeian has received several accolades for his contributions to epidemiology and public health, including recognition for his impactful research publications and involvement in various health initiatives. His work continues to inspire future generations of health professionals. πŸ†

Publication Top Notes

Dr. Rezaeian has authored numerous significant publications in reputable journals, contributing to the scientific community’s understanding of epidemiology and public health. Some notable works include:

Influenza A (H1N1) in Hamedan Province, Western Iran in 2009: A Case-Control Study (2010, J Res Health Sci) – Cited by 30

Quality of Cohort Studies Reporting Post the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (2011, Epidemiology and Health) – Cited by 50

The Quality of the Reporting of Randomized Controlled Trials after CONSORT Statement in the Prestigious Journals (2013, Shiraz E Medical Journal) – Cited by 40

Difference in the Incidence of Congenital Hypothyroidism Among World Countries (2013, Ann Saudi Med) – Cited by 20

Social Determinants of Health Associated with Self-Reported HIV Testing Among Women (2013, Iran J Public Health) – Cited by 35

Risk Factors of Congenital Hypothyroidism Using Propensity Score: A Matched Case-Control Study (2013, J Res Health Sci) – Cited by 25